InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 271

Monday, 03/06/2023 6:00:29 PM

Monday, March 06, 2023 6:00:29 PM

Post# of 572
I believe you are correct that Ven is the main driver of myelosuppression in the Flt3/Ven combos. That said we don't know if lower doses of Ven may be effective in a TUSP/Ven combo. We don't know the dose titration plans for TUSP/Ven yet.

In any event, Gilteritinib and Quizartinib bring other toxicities such as QTc elongation and DS into the combination picture.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News